Psychedelic Therapeutics Clinical Trials Research Report 2024 Featuring Yale University, Johnson & Johnson, Shire Pharmaceuticals, Pfizer, Lykos, And UCB

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Sept. 13, 2024 (GLOBE NEWSWIRE) -- The "Clinical Trials: Psychedelic Therapeutics" report has been added to ResearchAndMarkets.com's offering.
This report provides a review of global psychedelic therapeutic clinical trials. The aim of this report is to identify key analyses and segmentations of these trials. As the number of psychedelic therapeutic clinical trials continues to increase, a deeper understanding of these trials, such as sponsor type, location, and phase, are reviewed.
Scope

• Non-industry sponsors outnumber industry sponsors for psychedelic therapy trials. They account for 58% of psychedelic therapy trials, with the largest margin of difference seen in 2021.
• Yale University is the leading non-industry sponsor while Johnson & Johnson is the leading industry sponsor.
• Central nervous system is by far the top therapy area for psychedelic therapy trials, tested in 92% of all psychedelic therapy trials. The top indication is depression.
• At the country level, the US leads with 88% of all North American studies, followed by China.
• Phase II trials of psychedelic therapies have outnumbered all other phases since 2013.

Reasons to Buy

• Identifies and analyzes psychedelic therapeutic clinical trials by multiple trial designs, such as trial start year, geographic distribution, phase and drug details.
• Examines the cause of the increase of psychedelic clinical trials.
• Gives reasons for certain trends seen in psychedelic trials.
• Breaks down trials by sponsor type and top sponsors.
• Looks at the virtual components used for psychedelic trials.
• Describes the leading drugs used in psychedelic trials.

Companies Featured

• Yale University
• Johnson & Johnson
• Shire Pharmaceuticals
• Pfizer
• Lykos
• UCB

Key Topics Covered:
1 Table and Figures
2 Executive Summary
3 Introduction

• Report Scope
• Methodology

4 Psychedelic Therapeutic Trials

• Number of psychedelic therapy trials, by status (2003-24)
• Psychedelic therapy trials, by regional distribution (2013-24)
• Number of Psychedelic therapy trials, by top five countries (2018-24)
• Number of Psychedelic therapy trials, by top five US States
• Psychedelic therapy clinical trials, by year and phase (2013-24)
• Psychedelic clinical trials, by sponsor type (2004-24)
• Psychedelic clinical trials, by top 10 non-industry sponsors
• Psychedelic clinical trials, by top 10 industry sponsors
• Terminated/suspended/withdrawn psychedelic therapy clinical trials, by leading sponsors
• Terminated/suspended/withdrawn psychedelic therapy clinical trials, by leading reason
• Number of psychedelic clinical trials, by virtual component and type of mobile healthcare
• Single-country and multinational psychedelic therapy trials, by region
• Top 10 indications in psychedelic therapy clinical trials, by phase
• Top 10 psychedelic therapies, by clinical trial count
• Top five psychedelic drugs with highest drug-specific likelihood of approval

6 Key Findings
7 Appendix

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN13092024004107003653ID1108670500